Overview
LFST market data
Price History
LFST price chart
Valuation & Profitability
- P/E (TTM)
- 195.99 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 1.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.39 – $12.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.5B · P/B 1.80 · P/S 3.04.
Company News
JP Morgan Maintains Neutral on LifeStance Health Gr, Raises Price Target to $13Benzinga · Aug 14, 2026, 4:04 PM
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $16Benzinga · Aug 7, 2026, 9:35 AM
LifeStance Health Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, the company issued Q3 sales guidance above estimates.Benzinga · Aug 6, 2026, 11:49 AM
LifeStance Health Gr Sees Q3 Sales $420.000M-$440.000M vs $418.474M EstBenzinga · Aug 6, 2026, 10:15 AM
LifeStance Health Gr Raises FY2026 Sales Guidance from $1.640B-$1.680B to $1.685B-$1.725B vs $1.665B EstBenzinga · Aug 6, 2026, 10:15 AM
LifeStance Health Gr Q2 EPS $0.06 Beats $0.04 Estimate, Sales $435.354M Beat $414.577M EstimateBenzinga · Aug 6, 2026, 10:14 AM
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $15Benzinga · Jul 24, 2026, 10:22 AM
'Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails' - BloombergBenzinga · Jul 23, 2026, 2:14 PM
Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jul 21, 2026, 11:51 AM
Canaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $13Benzinga · Jul 21, 2026, 11:36 AM